Fig. 1

Kaplan Meier curve of percentage of sustained MR^4.5 after discontinuation. a In the overall population, 2-year estimate: 64%, 95% CI [53, 73]. b According to duration of TKI treatment (< 87 months vs ≥ 87 months). c According to type of frontline treatment (TKI vs interferon). d According to type of frontline and only TKI (imatinib vs dasatinib vs nilotinib). e According to lines of treatment (first line vs two or more line). f According to duration to achieve MR^4.5 (< 17 months vs ≥ 17 months). g According to sustained MR^4.5 duration before discontinuation (< 72 months vs ≥ 72 months). h According to reason of discontinuation (elective vs adverse events)